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Abstract
Introduction Heat shock protein 90 (HSP90) is a key
component of a multichaperone complex involved in the post-
translational folding of a large number of client proteins, many of
which play essential roles in tumorigenesis. HSP90 has
emerged in recent years as a promising new target for
anticancer therapies.
Methods The concentrations of the HSP90 inhibitor NVP-
AUY922 required to reduce cell numbers by 50% (GI50 values)
were established in a panel of breast cancer cell lines and
patient-derived human breast tumors. To investigate the
properties of the compound in vivo, the pharmacokinetic profile,
antitumor effect, and dose regimen were established in a BT-
474 breast cancer xenograft model. The effect on HSP90-p23
complexes, client protein degradation, and heat shock response
was investigated in cell culture and breast cancer xenografts by
immunohistochemistry, Western blot analysis, and
immunoprecipitation.
Results We show that the novel small molecule HSP90 inhibitor
NVP-AUY922 potently inhibits the proliferation of human breast
cancer cell lines with GI50 values in the range of 3 to 126 nM.
NVP-AUY922 induced proliferative inhibition concurrent with
HSP70 upregulation and client protein depletion – hallmarks of
HSP90 inhibition. Intravenous acute administration of NVP-
AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-
474 breast tumors resulted in drug levels in excess of 1,000
times the cellular GI50 value for about 2 days. Significant growth
inhibition and good tolerability were observed when the
compound was administered once per week. Therapeutic
effects were concordant with changes in pharmacodynamic
markers, including HSP90-p23 dissociation, decreases in
ERBB2 and P-AKT, and increased HSP70 protein levels.
Conclusion NVP-AUY922 is a potent small molecule HSP90
inhibitor showing significant activity against breast cancer cells
in cellular and in vivo settings. On the basis of its mechanism of
action, preclinical activity profile, tolerability, and pharmaceutical
properties, the compound recently has entered clinical phase I
breast cancer trials.
Introduction
Targeted therapy against an oncogenic molecule or pathway
has produced promising results for various hematological
malignancies and solid tumors, such as imatinib against
chronic myelogenous leukemia [1], gefitinib against lung can-
cer [2], bevacizumab and cetuximab against colon cancer [3],
and tamoxifen and trastuzumab against breast cancer [4].
However, considering the complexity of breast cancer with its
multiple genetic abnormalities and resistance development
against current therapies, targeting a single pathway by
17-AAG = tanespimycin; ANOVA = analysis of variance; ATCC = American Type Culture Collection; D5W = 5% glucose in water; DMEM = Dul-
becco's modified Eagle's medium; EGFR = epidermal growth factor receptor; ER = estrogen receptor; FCS = fetal calf serum; GI50 = the concen-
tration that inhibits cell growth by 50%; HPLC = high-pressure liquid chromatography; HSP90 = heat shock protein 90; i.v. = intravenous; MS-MS 
= tandem mass spectrometry; PD = pharmacodynamic; PI3K = phosphahtidylinositol-3-kinase; PVDF = polyvinylidene fluoride; s.c. = subcutaneous.Breast Cancer Research    Vol 10 No 2    Jensen et al.
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inhibiting the activity of one component is unlikely to be effec-
tive in the long term. Thus, identification of molecular targets
that modulate multiple components of one or several signaling
pathways in a nongenotoxic manner would be desired for anti-
cancer drug discovery. For this reason, heat shock protein 90
(HSP90) has attracted considerable interest in recent years as
a potential therapeutic target for the identification and devel-
opment of a new generation of anticancer drugs to treat breast
cancer and other malignancies [5].
HSP90 is a ubiquitously expressed molecular chaperone play-
ing an important role in the post-translational conformational
maturation and activation of a large number of client proteins
that have been implicated in oncogenesis [6]. HSP90 is func-
tional as a dimer and operates in a highly regulated ATP-fueled
cycle together with a group of cochaperones (see [7] for a cur-
rent overview). Inhibition of the ATPase activity at the N-termi-
nus of HSP90 is being exploited by all inhibitors that have
entered the clinic so far. Currently, the most advanced HSP90
inhibitors in clinical trials are of the benzoquinone ansamycin
class, which have shown promising activity in human tumor
xenograft models [6,8] and are currently undergoing phase II/
III clinical trials in solid tumors and hematological malignan-
cies. The most studied compound of this class, tanespimycin
(17-AAG), has relatively poor physiochemical properties, mak-
ing formulation for clinical delivery a challenge [9]. This issue
has been addressed, in part, through the identification of the
water-soluble analog alvespimycin (17-DMAG) [8], but the
development of HSP90 inhibitors with more favorable pharma-
ceutical properties is being intensely pursued.
Breast cancer is a prime target indication for HSP90 inhibitors
due to the relatively good understanding of the role of this
chaperone in the turnover and folding of steroid hormone
receptors [10-13]. The estrogen receptor (ER) antagonist
tamoxifen is used as the standard of care in patients with ER-
positive breast cancer [14]. However, there is medical need
for alternative treatment strategies since most tumors eventu-
ally develop tamoxifen resistance even if they remain ER-posi-
tive [15]. In addition to ER, a number of other HSP90 client
proteins have been shown to be involved in breast cancer pro-
gression such as those that are important for signaling through
the phosphahtidylinositol-3-kinase (PI3K/p110α)/protein
kinase B (PKB/AKT) pathway, including epidermal growth fac-
tor receptor (EGFR) 1 and 2 (ERBB2) and AKT [16,17]. In
fact, one of the most well-defined client proteins in breast can-
cer is the receptor tyrosine kinase ERBB2/Her2/EGFR2.
Overexpression of this protein in breast tumors leads to acti-
vation of the PI3K/AKT pathway [18]. This pathway is onco-
genic in many tumors by controlling processes such as cell
growth, proliferation, and generation of survival signals
[19,20]. HSP90 inhibitors affect AKT activity indirectly
through depletion of upstream signaling molecules (for exam-
ple, ERBB family members) and directly by preventing
HSP90-dependent conformational stability of AKT [17,21,22].
In this report, we demonstrate that the novel small molecule
compound NVP-AUY922 potently inhibits HSP90 in vitro, has
good pharmaceutical and pharmacological properties, and
exhibits potent antitumor activity at tolerated doses in an ER-
and ERBB2-positive human breast cancer model. The data
provide a preclinical rationale to support phase I clinical trials
with NVP-AUY922 in patients with breast cancer.
Materials and methods
NVP-AUY922 solution and formulation
The identification and structure of NVP-AUY922 have been
described in detail elsewhere [23]. For in vitro experiments,
stock solutions of NVP-AUY922 were prepared in 100%
dimethyl sulfoxide at 10 mM and stored at -20°C. For intrave-
nous (i.v.) administration, the free base of NVP-AUY922 was
formulated in 60 mM lactic acid or 2.5% ethanol, 20% 50 mM
tartaric acid, 77.5% (5% glucose in water [D5W] containing
1% Tween 80) vol/vol. An optimized NVP-AUY922 salt with
high solubility in aqueous solutions was formulated in D5W for
i.v. administration and delivered in a volume of 10 mL/kg.
Established cell lines and patient-derived primary 
tumors
Established cell lines were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA, USA) and cultured
in Dulbecco's modified Eagle's medium (DMEM)/F-12 supple-
mented with 10% fetal calf serum (FCS), with the exception of
BT-474 cells, which were cultured in DMEM supplemented
with 10% FCS. A clonogenic assay from primary human
breast tumors was performed in a 24-well format as described
[24] (Oncotest GmbH, Freiburg, Germany). Briefly, serially
passaged solid human xenografts growing subcutaneously in
nude mice (NMRI nu/nu strain) were disaggregated, and 4 ×
104 to 8 × 104 viable cells were added to 0.2 mL of Iscove's
medium (supplemented with 20% vol/vol FCS and 1% vol/vol
gentamicin) containing 0.4% agar and plated on top of the
base layer (0.75% agar). After 24 hours, drug was added in an
additional 0.2 mL of medium and incubated at 37°C in a
humidified atmosphere containing 7.5% CO2. At the time of
maximum colony formation (8 to 20 days), counts were per-
formed with an automatic image analysis system (OMNICON
FAS IV; Bio-Sys GmbH, Karben, Germany).
Western blot analysis and immunoprecipitation
Protein expression analysis in the panel of seven established
breast cancer cell lines was assessed by Western blotting.
Total cell extracts were prepared and electrophoresed in
SDS-polyacrylamide gel and transferred to polyvinylidene flu-
oride (PVDF) membrane (Millipore Corporation, Billerica, MA,
USA). The following antibodies were used for immunoblotting:
Her3 (sc-285; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), Her2 (ab8054; Abcam, Cambridge, UK), phos-
phor-Her2 (Tyr1248) (44&#8211900, Invitrogen Corporation,
Carlsbad, CA, USA) EGFR (#2232; Cell Signaling Technol-
ogy, Inc., Danvers, MA, USA), phosphor-Akt (Ser473)Available online http://breast-cancer-research.com/content/10/2/R33
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(#9271; Cell Signaling Technology, Inc.), Akt (#9272, Cell
Signaling Technology, Inc.), ER-α (sc-542; Santa Cruz Bio-
technology, Inc.), PI3K (p110α) (#4254; Cell Signaling Tech-
nology, Inc.), PDK1 (#3062; Cell Signaling Technology, Inc.),
HSP70 (SPA-810; Stressgen Bioreagents, now part of Assay
Designs, Inc., Ann Arbor, MI, USA), HSP90 (SPA-845; Assay
Designs, Inc.), Hsc70 (sc-7298, Santa Cruz Biotechnology,
Inc.), Rb (#9309; Cell Signaling Technology, Inc.), pMEK1/2
(#9121, Cell Signaling Technology, Inc.), pERK (#9101; Cell
Signaling Technology, Inc.), Bax (#2772, Cell Signaling Tech-
nology, Inc.), Bcl-2 (sc-492; Santa Cruz Biotechnology, Inc.),
Bad (#9292; Cell Signaling Technology, Inc.), Bad (#9292;
Cell Signaling Technology, Inc.), and Bcl-XL (#2762; Cell Sig-
naling Technology, Inc.).
To assess total levels of AKT, phosphorylated AKT, β-tubulin,
and ERBB2 in the cell extracts, 20 to 30 μg of total protein
was resolved by the appropriate-percentage SDS-PAGE. The
following antibodies were used for immunoblotting: anti-AKT
(cat. no. 9272, rabbit polyclonal; Cell Signaling Technology,
Inc.), anti-phospho-AKT (Ser473) (cat. no. 9271, rabbit poly-
clonal; Cell Signaling Technology, Inc.), anti-β-tubulin (cat. no.
T 4026, mouse monoclonal, clone Tub2.1; Sigma-Aldrich, St.
Louis, MO, USA), and anti-ERBB2 (cat. no. 28-0004, rabbit
polyclonal; Zymed Laboratories Inc., now part of Invitrogen
Corporation, Carlsbad, CA, USA). Bound antibodies on PVDF
immunoblots were detected by Amersham ECL (Amersham,
now part of GE Healthcare, Little Chalfont, Buckinghamshire,
UK) or infrared fluorescence detection (LI-COR Biosciences,
Lincoln, NE, USA).
For immunoprecipitation, 300 μg of total protein was immuno-
precipitated with 5 μg of rat anti-HSP90α monoclonal anti-
body (SPA-840, clone 9D2, isotype: IgG2a; Assay Designs,
Inc.). Proteins were resolved by 12% SDS-PAGE and trans-
ferred to PVDF membranes. The antibodies used were an anti-
HSP90α antibody (cat. no. SPS-771, rabbit polyclonal; Assay
Designs, Inc.) and an anti-p23 antibody (cat. no. ALX-804-
023, mouse monoclonal, clone JJ3, isotype: IgG1; ALEXIS
Corporation, Lausen, Switzerland).
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were
stained using the Ventana Discovery System (Ventana Medi-
cal Systems, Inc., Tucson, AZ, USA). Deparaffinization of tis-
sue sections and heat-induced epitope retrieval using
Standard Cell Conditioning Solution 1 (Ventana Medical Sys-
tems, Inc.) were performed directly on the System. A rabbit
anti-human ERBB2 (HER2) monoclonal antibody (Lab Vision
Corporation, Fremont, CA, USA) and a mouse anti-human
HSP70 (Assay Designs, Inc.) were prepared in Dako diluent
(Dako North America, Inc., Carpinteria, CA, USA) and used at
concentrations of 2 ug/mL for 32 minutes and 10 ug/mL for 60
minutes, respectively. For HSP70 staining, slides were incu-
bated with a biotin-labeled anti-mouse IgG1 (Research Diag-
nostics, Inc., now known as Fitzgerald Industries International,
Concord, MA, USA) at a concentration of 1.25 ug/mL diluted
in M.O.M. (Mouse-on-Mouse) (Vector Laboratories, Peterbor-
ough, UK). Detection using a 3,3'-diaminobenzadine reaction
was performed on the section by using the Ventana OmniMAP
DAB for the ERBB2 antibody and the Ventana DAB Map rea-
gent for the HSP70 antibody (Ventana Medical Systems, Inc.).
Each tissue section was subsequently counterstained with
hematoxylin. To ensure antibody specificity, consecutive tissue
sections were incubated with normal isotype-matched immu-
noglobulins (rabbit IgG; Jackson ImmunoResearch Laborato-
ries, Inc., West Grove, PA, USA, and mouse IgG1; Lab Vision
Corporation) used at concentrations equivalent to Her2 and
HSP70 antibodies. Stained tissue sections were quantified
using the Aperio Digital Pathology System (Aperio Technolo-
gies, Inc., Vista, CA, USA).
Breast cancer xenograft model and efficacy studies
The ER-positive ERBB2-overexpressing cell line BT-474,
which initially was derived from a human breast ductal carci-
noma established from a solid invasive ductal carcinoma of the
breast of a 60-year-old woman, was purchased from the
ATCC (HTB-20). The cells were grown in DMEM high glucose
(4.5 g/L) supplemented with 10% FCS, 200 mM l-glutamine,
and 1% sodium pyruvate (BioConcept, Allschwil, Switzer-
land). Two or three days prior to cell inoculation, each mouse
was subcutaneously implanted on the upper dorsal side with
a 17β-estradiol pellet (25 μg/day, 90-day release; Innovative
Research of America, Sarasota, FL, USA) using a trocar nee-
dle. BT-474 cells (5 × 106) were injected in 200 μL of
Matrigel/Hanks' balanced salt solution (1:1 vol) (BD Matrigel™
Basement Membrane Matrix; BD Biosciences, San Jose, CA,
USA) subcutaneously in the right flank. Invasive procedures
were performed under Forene anesthesia. All experiments
were performed using female Harlan HsdNpa: Athymic Nude-
nu mice that were obtained from Novartis internal breeding
stocks (Laboratory Animal Services, Novartis Pharma AG,
Basel, Switzerland). The animals were kept under optimized
hygienic conditions with 12-hour dark/12-hour light condi-
tions. The animals were fed food and water ad libitum. All ani-
mal experiments were performed in strict adherence to the
Swiss law for animal protection. The experimental protocols
were approved by the Swiss Cantonal Veterinary Office of
Basel-Stadt.
Tumor volume measurements
Treatment with NVP-AUY922 was initiated when the average
tumor volume reached approximately 100 mm3. Tumor growth
and body weights were monitored at regular intervals. The
xenograft tumor sizes were measured manually with calipers,
and the tumor volume was estimated using the formula (w × l
× h × π/6), where width (w), height (h), and length (l) are the
three largest diameters [25].Breast Cancer Research    Vol 10 No 2    Jensen et al.
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Pharmacokinetic analysis
Female athymic BT-474 tumor-bearing mice with tumors of
approximately 250 mm3 received an i.v. dose of 30 mg/kg of
NVP-AUY922. At various time points, mice (n = 4) were sacri-
ficed and blood and tissues (tumor, liver, lung, heart, and mus-
cles) were dissected. Concentrations of NVP-AUY922 in
plasma and tissues were determined by high-pressure liquid
chromatography/tandem mass spectrometry (HPLC/MS-MS)
operated in electrospray ionization-positive mode. Frozen tis-
sues were minced, then homogenized in an equal volume of
ice-cold phosphate-buffered saline (Sigma P4417; Sigma-
Aldrich) using a Polytron homogenizer (TP18-10; IKA,
Staufen, Germany) and keeping the material cold during the
homogenization. After the addition of 50 μL of internal stand-
ard (1 μg/mL) to analytical aliquots (25 to 250 μL) of plasma
or tissue homogenate, the proteins were precipitated by the
addition of an equal volume of acetonitrile and processed fur-
ther for chromatographic separation. After three repetitions of
protein precipitation by the addition of an equal volume of ace-
tonitrile followed always by evaporation to dryness, the sam-
ples were redissolved in 100 μL of acetonitrile/water (1/9 vol/
vol) containing 0.2% vol/vol formic acid. An aliquot (5 μL) of
this solution was separated on a RESECT™ Ultra Cyano
reverse-phase HPLC column (column size 50 × 1 mm, particle
size 3 μm, preceded by a guard column: Phenomenex™ AJO-
4304 Phenylpropyl, size 4 × 2 mm (Phenomenex, Torrance,
CA, USA)) with a mobile phase consisting of a mixture of 0.2%
formic acid in water (solvent A) and 0.2% formic acid in ace-
tonitrile (solvent B). The column eluent was introduced directly
into the ion source of the triple-quadrupole mass spectrometer
Quattro Ultima™ (Micromass Limited, now part of Waters Cor-
poration, Milford, MA, USA) controlled by Masslynx™ 4.0 soft-
ware. Positive electrospray ionization multiple-reaction
monitoring was used for the MS/MS detection of the analyte.
Precursors to product ion transitions of m/z 466.35 → m/z
308.20 for NVP-AUY922-NX and m/z 480.40 → m/z 308.15
for IS VER814 were used. The limits of quantification were set
to 4 ng/mL and 10 ng/g for plasma and tissues, respectively
(coefficient of variation and overall bias less than 30%).
Regression analysis and further calculations were performed
using QuanLynx™ 4.0 (Waters Corporation, Milford, MA, USA)
and Excel™ 2002 (Microsoft Corporation, Redmond, WA,
USA). Concentrations of unknown samples were calculated
from the peak area ratio of the product ion of the analytes to
the product ion of its internal standard (ordinate) against the
nominal concentration (abscissa). Assay linearity was indi-
cated by an overall regression coefficient of 0.9975.
Statistical analysis
When applicable, results are presented as mean ± standard
error of the mean. Tumor and body weight data were analyzed
by analysis of variance (ANOVA) with the post hoc Dunnett
test for comparison of treatment versus control groups. The
post hoc Tukey test was used for intragroup comparison. Sta-
tistical analysis was performed using GraphPad Prism 5
(GraphPad Software, Inc., San Diego, CA, USA). As a meas-
ure of efficacy, the %T/C value is calculated at the end of the
experiment according to (Δtumor volumetreated/Δtumor volume-
control) × 100, where Δtumor volumes represent the mean
tumor volume on the evaluation day minus the mean tumor vol-
ume at the start of the experiment.
Results and Discussion
NVP-AUY922 is a potent inhibitor of breast cancer cell 
proliferation in vitro
We have previously shown NVP-AUY922 to be a potent selec-
tive inhibitor of HSP90. In competitive fluorescence polariza-
tion assays, NVP-AUY922 inhibited HSP90α and HSP90β
with similar IC50 (median inhibition concentration) values of 13
and 21 nM [23,26], respectively. In a representative panel of
human tumor cell lines (including prostate, breast, ovarian,
colon, lung, melanoma, and glioblastoma), NVP-AUY922
inhibited cell proliferation with low nanomolar potency; GI50
(the concentration that inhibits cell growth by 50%) values
were in the range of 2.3 to 50 nM [23]. To better elucidate the
clinical utility of NVP-AUY922, we investigated the effects of
the compound against a panel of human breast cancer cell
lines. NVP-AUY922 was potent against six of the seven breast
cancer cell lines tested, inhibiting in vitro growth with an aver-
age GI50 value of 5.4 nM (Table 1). When compared directly
with 17-AAG, NVP-AUY922 was between 3.6- and 300-fold
more active at inhibiting tumor cell growth. MDA-MB-157
exhibited around a 14-fold reduced sensitivity to NVP-
AUY922 compared with the next most insensitive cell line. In
an attempt to understand the differential cellular response of
HSP90 inhibition by NVP-AUY922, the expression levels of
HSP90, HSP70, various client proteins (EGFR1/Her1,
ERBB2, AKT, and ER), and those involved in apoptotic
responses (Bax, Bad, and Bcl-XL) were determined (Figure
1a). No clear correlation between protein expression or phos-
phorylation status and cell line response could be ascertained.
More plain was the heterogeneity in pathway composition
between the various cell lines. BT-474 and SKBr3 have often
been used to examine the effects of HSP90 inhibitors in high
ERBB2 expressing breast cancer cell lines. However, they dif-
fer quite markedly in the expression of other factors (such as
p110α) central to this pathway. Therefore, attempting to
define sensitive clinical populations via the expression of a sin-
gle client protein or a limited number of client proteins may not
be a suitable approach, in particular when a substantial
number of proteins can be affected by HSP90 modulation. To
further evaluate the efficacy of NVP-AUY922 against human
breast tumors, the ability of NVP-AUY922 to inhibit the colony-
forming potential of primary tumor stem cells growing in soft
agar was examined [24]. Tumor cells were derived from
patient samples directly transplanted to and subsequently
serially passaged in nude mice. This clonogenic assay system
may better reflect the in vivo situation than in vitro assays
using established tumor cell lines and has been shown to be
predictive for further in vivo evaluation of anticancer drugsAvailable online http://breast-cancer-research.com/content/10/2/R33
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[27]. NVP-AUY922 was highly effective at inhibiting the
growth of five out of the six human breast cancer explants
tested, with average GI50 and GI70 (the concentration that
inhibits cell growth by 70%) values of 191 and 379 nM,
respectively (Table 2). One of the tumor explants was highly
resistant to NVP-AUY922 treatment, exhibiting a GI50 value of
greater than 10 μM (the highest concentration evaluated).
NVP-AUY922 induces HSP90-p23 dissociation and client 
protein depletion in a concentration- and time-
dependent manner
The classic method of following the cellular activity of HSP90
inhibitors is through the proteasome-dependent degradation
of HSP90 client proteins such as ERBB2 and AKT and the
concomitant loss of signaling through the affected pathways
as determined by, for example, decreased AKT phosphoryla-
tion. This method, however, does not directly demonstrate that
the catalytic activity of HSP90 has been blocked. An alterna-
tive method of studying the cellular effects of HSP90 inhibi-
tors, which more closely monitors the catalytic cycle of
HSP90, is through the evaluation of disruption of the HSP90-
p23 complex [28]. HSP90 recruits various cochaperones at
different points in its catalytic cycle, and the association of
HSP90 with p23 is essential for HSP90 activity and client pro-
tein stability. HSP90-p23 interaction requires ATP binding but
not ATP hydrolysis in biochemical assays, and p23 specifically
recognizes HSP90-ATP complexes but not HSP90 alone
[28]. Thus, treatment with the ATP competitive inhibitor 17-
Figure 1
Protein expression analysis in a panel of human breast cancer cell lines and effect of NVP-AUY922 on the HSP90-p23 complex in BT-474 cells Protein expression analysis in a panel of human breast cancer cell lines and effect of NVP-AUY922 on the HSP90-p23 complex in BT-474 cells. (a) 
The expression of HSP90 and specific proteins affected by HSP90 inhibition (Her3 [EGFR3], Her2 [ErbB2, EGFR2], phospho Her2 [pHer2], 
EGFR, AKT [PKB], phospho-AKT [pAkt], estrogen receptor-alpha [ERa], PI3K [p110α], PDK1, HSP70, Hsc70, Rb, pMEK1/2, pERK, Bax, Bcl-2, 
Bad, and Bcl-XL) was analyzed in seven human breast cancer cell lines (BT20, BT-474, MDA-MB-157 [MB-157], MDA-MB-231 [MB-231], MDA-
MB-468 [MB-468], SKBr3, and MCF-7) by Western blot analysis. (b) The ERBB2-overexpressing and estrogen receptor-positive cell line BT-474 
was chosen for studies of the kinetics and concentration-dependent dissociation of HSP90-p23 complexes and client proteins in the presence of 
NVP-AUY922 or tanespimycin (17-AAG). The amount of p23 associated with HSP90 was determined by immunoprecipitating p23 followed by 
immunoblotting for HSP90. The levels of ERBB2, AKT, phosphorylated AKT and β-tubulin were determined by immunoblotting. DMSO, dimethyl sul-
foxide; HSP90, heat shock protein 90.Breast Cancer Research    Vol 10 No 2    Jensen et al.
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AAG results in the dissociation of the HSP90-p23 complex, a
feature that recently has been exploited in human cell lines and
xenograft using a split HSP90-p23 Renilla luciferase protein
fragment-assisted complementation assay [29]. Destabiliza-
tion of the HSP90-p23 interaction in tumor cells and the sub-
sequent measurement using immunoprecipitation therefore
can be used to monitor the effect of HSP90 inhibitors on the
HSP90 catalytic cycle (Figure 1b). In BT-474 cells, NVP-
AUY922 and 17-AAG caused a concentration-dependent
decrease in the amount of HSP90α co-immunoprecipitating
with p23. NVP-AUY922 appears to be more potent than 17-
AAG at inhibiting the HSP90-p23 interaction. This observa-
tion is in accordance with the increased cellular growth inhibi-
tion potency obtained with NVP-AUY922 in comparison with
17-AAG (Table 1). The inhibition of the HSP90-p23 associa-
tion occurs rapidly following addition of both compounds.
Specifically, NVP-AUY922 causes HSP90-p23 complex dis-
sociation to happen within 5 minutes and complete effect to
happen within 15 minutes. For 17-AAG, the time to onset of
complex destabilization is slightly delayed compared with
NVP-AUY922 but full inhibition still occurs within 15 minutes
(Figure 1b). To confirm that complex destabilization was
affecting client protein status, we correlated complex dissoci-
ation by immunoprecipitation with client protein degradation.
Treatment of BT-474 cells with 50 nM NVP-AUY922 caused
a clear dissociation between p23 and HSP90α, resulting in
the loss of HSP90α from p23 immunoprecipitates (Figure 1b).
This clearly coincided with a decrease in total ERBB2 levels
and subsequent inhibition of downstream signaling as meas-
ured by a decrease in the levels of phospho-AKT. Under these
experimental conditions, significant reduction of protein AKT
levels requires a higher NVP-AUY922 concentration of around
1 μM.
Biodistribution measurements
Since NVP-AUY922 exhibited a strong antiproliferative effect
against established and primary breast cancer cells (Tables 1
and 2), we evaluated the properties of the compound in vivo.
To this end, a breast cancer xenograft model based on the BT-
474 cell line was established. The antitumor effect of 17-AAG
has been thoroughly evaluated in this model, which is known
to be highly sensitive to HSP90 inhibitors when grown as sub-
cutaneous (s.c.) xenograft tumors [21,30]. This cell line is
expressing high levels of ERBB2 and ER-α (Figure 1a) and
depends on exogenous estrogen supplement for growth as
s.c. xenografts in athymic nude mice. The biodistribution and
pharmacokinetic profile of NVP-AUY922 was determined by
HPLC/MS-MS (Figure 2a). The pharmacokinetic parameters
derived from these data are summarized in Table 3. We found
that NVP-AUY922 is rapidly distributed from the bloodstream
into tissues and has a short half-life in plasma. Plasma clear-
ance was 8.9 L/hour and a large volume of distribution of 18.9
L was determined. The pharmacokinetic profile of NVP-
AUY922 is characterized by a biphasic decline in plasma.
Plasma concentrations were below levels of quantitation 48
hours after compound administration. The apparent terminal
elimination half-life for NVP-AUY922 in plasma was 10 hours
based on the last three time points. The dose-normalized
plasma exposure following i.v. dosing at 20 mg/kg resulted in
a similar value as with 30 mg/kg (0.28 versus 0.24 hours*
μmol/L), indicating dose linearity within this dose range (data
not shown). The tissue exposures over the course of 48 hours
were 5*fold (muscle and heart), 7*fold (liver), and 10*fold
(lung) greater than in plasma. The terminal elimination half-life
from the analyzed non-tumor tissues was between 5.5 and 8
hours. Importantly, the tumor exposure was approximately
47*fold higher than that in plasma, maintaining a concentration
of 2.22 nmol/g 48 hours after compound administration. This
drug level corresponded to approximately 13% of the Cmax
(highest concentration) (16.3 nmol/g) and resulted in a termi-
nal half-life of 25 to 30 hours. Interestingly, retention in tumor
xenografts was also observed for 17*AAG [31], indicating that
this may be a target-related phenomenon.
NVP-AUY922 affects pharmacodynamic markers in vivo
The biodistribution and pharmacokinetic profile of NVP-
AUY922 in the BT-474 xenograft model encouraged us to
assess whether NVP-AUY922 is capable of directly interfering
with the catalytic cycle of HSP90 with concomitant depletion
of HSP90 client proteins in vivo (Figure 2b). To asses whether
systemic administration of NVP-AUY922 could affect the
association between p23 and HSP90 observed in vitro,
HSP90α was immunoprecipitated and co-immunoprecipitat-
ing p23 was detected by Western blotting. A significant effect
of NVP-AUY922 on HSP90-p23 complex dissociation was
observed at the 2- and 6-hour time points. From 16 and 24
hours after compound administration, HSP90-p23 complexes
reassembled in the BT-474 xenografts. To asses whether the
effect of AKT phosphorylation on Ser473 observed on cell
Table 1
Antiproliferative effect of NVP-AUY922 against a panel of 
human breast cancer cell lines
Cell line ErbB2/ER status NVP-AUY922 17-AAG
nM
BT-474 ErbB2+/ER+ 3.1 ± 1.4 17.4 ± 5.2
BT20 ErbB2-/ER- 4.0 ± 1.4 18.9 ± 4.8
MDA-MB-157 ErbB2-/ER- 126 ± 37 29.5 ± 20.8
MDA-MB-231 ErbB2-/ER- 7.0 ± 1.7 2,057 ± 571
MDA-MB-468 ErbB2-/ER- 6.3 ± 2.6 1,657 ± 390
SkBr3 ErbB2+/ER- 3.3 ± 0.9 11.9 ± 8.0
MCF-7 ErbB2-/ER- 8.8 ± 1.8 69.0 ± 18.3
The concentrations of NVP-AUY922 and tanespimycin (17-AAG) 
that inhibit cell number by 50% (GI50) were determined. ErbB2 and 
estrogen receptor (ER) status is indicated.Available online http://breast-cancer-research.com/content/10/2/R33
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lines grown in culture could be observed in the xenograft
model, Western blot analysis was performed. We observed
that the inhibition of HSP90 by a single dose of NVP-AUY922
was paralleled by reductions in phospho-AKT levels. Thus,
NVP-AUY922 inhibits the catalytic cycle of HSP90 and
reduces AKT signaling in xenograft tumor tissues, which is
similar to the effects observed in vitro. Another hallmark of
HSP90 inhibition is the induction of a heat shock response,
which was evaluated by determining the HSP70 protein levels
by immunohistochemistry (Figure 3). In this experiment, a sin-
gle 50 mg/kg dose of NVP-AUY922 was administered to BT-
474 xenograft-bearing mice and tumor sections were pre-
pared at selected time points over the following week (Figure
3a). The staining intensity was quantified using automated
imaging analysis (Figure 3b) and already demonstrated
strongly increased HSP70 staining 6 hours after compound
administration. The staining intensity peaked at the 24-hour
time point and gradually returned to baseline over one week
(Figure 3b). These data demonstrated a delayed heat shock
response compared with the early response observed on the
HSP90-p23 complex and AKT phosphorylation. Next, we
determined the expression levels of the client protein ERBB2
in the same experiment by immunohistochemistry and West-
ern blot analysis (Figure 3c). ERBB2 levels were reduced from
6 to 18 hours after administration of NVP-AUY922 but
returned to baseline between 24 and 48 hours after the admin-
istration. Overall, the data suggest that a cascade of timely
events was initiated in which inhibition of HSP90 ATPase
activity leads to immediate HSP90-p23 dissociation followed
by inhibition of downstream signaling as detected by
decreased phosphorylation of AKT and degradation of client
proteins (for example, ERBB2) concomitant with release of
HSF-1, causing transcriptional induction of HSP70.
Lowest dose that elicits pharmacodynamic response in 
tumors
The lowest dose of NVP-AUY922 which could elicit a detect-
able response on HSP90-p23 complexes as well as AKT
phosphorylation was determined. The effect of NVP-AUY922
on selected pharmacodynamic (PD) markers was assessed by
administering the drug intravenously to s.c. BT-474 tumor-
bearing mice. A single dose of 8.3 or 25 mg/kg was adminis-
tered and tumors were dissected 6 hours later since HSP90-
p23 dissociation and AKT phosphorylation are easily detecta-
ble at this time point (Figure 2b). A dose of 25 mg/kg NVP-
AUY922 caused significant disruption of HSP90-p23 com-
plexes, whereas the 8.3 mg/kg dose caused only a subtle
disruption (Figure 3d). Only the highest dose of 25 mg/kg
Table 2
Antiproliferative effect of NVP-AUY922 against primary breast 
cancer
Cell line IC50 IC70
nM
MAXF 1162 304 505
MAXF 1322 29 48
MAXF 1384 209 477
MAXF 401 78 295
MAXF 574 >10,000 >10,000
MAXF 583 333 569
The concentrations of NVP-AUY922 that inhibit colony formation by 
50% (IC50) or 70% (IC70) were determined (Oncotest GmbH, 
Freiburg, Germany) [24].
Figure 2
Pharmacokinetic/pharmacodynamic analysis of NVP-AUY922 in BT- 474 tumor-bearing nude mice Pharmacokinetic/pharmacodynamic analysis of NVP-AUY922 in BT-
474 tumor-bearing nude mice. A pharmacokinetic profile of NVP-
AUY922 in BT-474 tumor xenografts, plasma, and organs (liver, heart, 
lung, and muscle) after administration of a single dose is shown. 
Female athymic mice bearing subcutaneous xenotransplants of the 
human ductal breast carcinoma BT-474 of approximately 250 mm3 
received a single dose of 30 mg/kg of NVP-AUY922 (intravenous) at 0 
hours. (a) NVP-AUY922 concentrations were determined by HPLC/
MS-MS analysis using an internal standard method. The limits of quanti-
fication for plasma and tissues were set to 4.0 ng/mL and 10 ng/g, 
respectively. Bars represent standard error of the mean (n = 4). (b) 
Pharmacodynamic analysis in BT-474 xenografts following a single 
NVP-AUY922 dose. The amount of p23 associated with HSP90 was 
determined by immunoprecipitating HSP90 followed by immunoblot-
ting for p23. The levels of AKT, phosphorylated AKT and β-tubulin were 
determined by immunoblotting. HPLC/MS-MS, high-pressure liquid 
chromatography/tandem mass spectrometry; HSP90, heat shock pro-
tein 90; IP, immunoprecipitation.Breast Cancer Research    Vol 10 No 2    Jensen et al.
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NVP-AUY922 elicited a reduction in phospho-AKT levels.
Thus, even though 8 mg/kg NVP-AUY922 appeared to cause
a slight reduction in HSP90-p23 complexes, the remaining
complexes are likely sufficient to maintain downstream signal-
ing as evidenced by AKT phosphorylation.
NVP-AUY922 exhibits potent antitumor activity at well-
tolerated dose levels against an ERBB2-overexpressing 
ER-positive breast cancer xenograft
During the drug discovery selection process for the optimal
development candidate, NVP-AUY922 was administered
intraperitonealy once per day to HCT16 colon tumor
xenograft-bearing mice at a dose of 50 mg/kg [23]. Apart from
demonstrating the antitumor potential of the compound, this
study demonstrated that NVP-AUY922 did not cause signifi-
cant body weight changes when administered intraperitonealy
at dose levels of up to 50 mg/kg daily [23]. We wanted to
elaborate on these initial findings by investigating whether the
effect observed on the PD markers correlated with an antitu-
mor effect at well-tolerated doses and regimens in the BT-474
tumor model. During the establishment of the BT-474 model,
we noticed that untreated tumor- and estrogen pellet-bearing
mice generally either lost or gained minimum body weight dur-
ing the experiment (data not shown and Figure 4, right panels).
The body weight loss is likely to make the animals more sensi-
tive to the potential additional toxicity caused by the treatment.
As such, this xenograft model is ideally suited for use to opti-
mize the dosing regimen that gives a good efficacy/tolerability
balance. To more closely simulate the administration route to
be used in clinical trials, the administration schedule was opti-
mized using i.v. administration of NVP-AUY922 (Figure 4). In
the first experiment, a single dose of NVP-AUY922 was admin-
istered at around the lowest dose levels that elicited a reliable
PD marker response (Figure 3d). Either 17 or 25 mg/kg was
administered and tumor growth was monitored for 21 days
(Figure 4a). A single administration at these dose levels did not
affect body weights compared with vehicle. However, at the
25 mg/kg dose level, significant tumor growth was not
observed for about 1 week after the administration. Also, at a
dose level of 17 mg/kg, an indication of retarded tumor growth
was observed (Figure 4a). Interestingly, at the end of the
experiment, the animals in the group treated with 25 mg/kg
had a tumor size corresponding to the tumor size in control ani-
mals approximately 10 days earlier and were statistically signif-
icantly smaller in this group compared with the control group
at the end of the experiment (P < 0.05, one-way ANOVA post
hoc Dunnett versus control). These results combined with PD
data showing a response lasting more than 24 hours clearly
demonstrated a likelihood of achieving good antitumor effi-
cacy when administering NVP-AUY922 in intermittent dose
regimens. To evaluate this hypothesis, we administered NVP-
AUY922 three times per week (Monday, Wednesday, and Fri-
day) at dose levels of 10, 30, and 50 mg/kg (Figure 4b).
Indeed, we achieved tumor regression at the two highest dose
levels whereas treatment at 10 mg/kg, which did not elicit a
reproducible effect on PD markers (Figure 3d), did not result
in a significant effect on tumor growth. Although these data
were highly encouraging, this treatment regimen resulted in a
significant body weight loss at all dose levels (Figure 4b, right
panel). To further improve the administration regimen, we eval-
uated whether extending the recovery period in between dos-
ing would improve tolerability without affecting antitumor
effect. Since tumor growth was blocked for about 1 week after
a single administration of NVP-AUY922 (Figure 4a), a once-a-
week dosing regimen was investigated. Groups of eight BT-
474 tumor-bearing animals were treated at dose levels of 8.3,
17, 25, 41, or 58 mg/kg. In this setting, NVP-AUY922 was
highly efficacious when a dose level of 25 to 58 mg/kg was
administered once per week (Figure 4c and Table 4). Dose
levels of 8.3 to 17 mg/kg did not result in a significant effect
on tumor growth compared with vehicle-treated control ani-
mals, correlating with the data demonstrating that to observe
a consistent PD response a single dose of 25 mg/kg is
needed (Figure 3d). Overall, we demonstrate that NVP-
AUY922 has good pharmacokinetic properties and is effica-
cious and well tolerated when administered as a single agent
once per week.
Conclusion
HSP90 has become an increasingly attractive target for anti-
cancer therapy [6]. HSP90 inhibitors cause pleiotropic effects
through degradation of a large number of client proteins as
well as induction of a heat shock response [32]. The simulta-
neous effect on multiple oncogenic pathways is predicted to
be beneficial in a broad spectrum of cancer types that are
driven by HSP90 client proteins. In this report, we focused on
provided preclinical data to support the use of NVP-AUY922
for the treatment of breast cancer, an indication that is cur-
Table 3
NVP-AUY922 biodistribution: pharmacokinetic parameters
Plasma Tumor Liver Muscle Heart Lung
Cmax, μmol/L or nmol/g 14.08 ± 4.14 16.36 ± 3.84 30.94 ± 5.58 27.45 ± 6.64 36.86 ± 7.42 48.48 ± 10.11
T 1/2 elimination λ_z, hours 10.3 30 7.7 8 5.6 5.5
AUC(0-8), hours* μmol/L or hours*nmol/g 7.3 345 53 35 32 71
The concentration of NVP-AUY922 was determined by high-pressure liquid chromatography/tandem mass spectrometry after a single intravenous 
administration of 30 mg/kg to BT-474 tumor-bearing mice. The highest concentration (Cmax), terminal half-life (T 1/2 elimination λ_z), and exposure as 
determined by the area under the curve (AUC) were determined for each organ, plasma, and BT-474 xenograft (tumor).Available online http://breast-cancer-research.com/content/10/2/R33
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rently being pursued in clinical trials. To this end, we demon-
strate that NVP-AUY922 exhibited significant antiproliferative
properties against most established and primary breast cancer
cells. A few breast cancer cell lines were found to be less sen-
sitive, which may be due to drug transporters or metabolic
activity. This is currently being investigated further.
The expression of a number of client proteins, signaling mole-
cules, heat shock response proteins, and proteins involved in
apoptotic pathways was determined. However, no clear corre-
lation between a specific pathway and antiproliferative effect
could be found. The majority of the work presented in this
report was performed in the BT-474 breast cancer cell line,
which is driven by ERBB2 and depends on estrogen for
growth. However, although ERBB2 is an excellent client pro-
tein, ERBB2-negative tumors may well be driven by suscepti-
ble client proteins and respond to HSP90 inhibitors. Based on
the antiproliferative profile in breast cancer cell lines, it is diffi-
cult to link NVP-AUY922 antitumor activity with a specific
genetic marker such as ERBB2 expression or ER status. This
makes patient stratification exceedingly difficult, as discussed
elsewhere [33].
NVP-AUY922 binds very potently to HSP90 in a competitive
biochemical assay [23,26]. The high biochemical potency cor-
related with the ability of NVP-AUY922 to directly interfere
with the HSP90-p23 complex both in BT-474 cells grown in
culture and as xenografts. However, for complete dissociation
of the HSP90-p23 complexes within 3 hours, a concentration
of approximately 15 times the BT-474 GI50 value (determined
after continuous exposure for 2 days) is needed. These data
suggest that complete inhibition of HSP90 is not needed to
achieve antiproliferative effect by continuous exposure. How-
ever, short-term exposure at high drug concentrations may
cause potent HSP90 inhibition in cells that are highly depend-
ent on HSP90, such as tumors [34]. The short-term exposure
causes the initiation of downstream events (for example, client
protein degradation) from which affected tumor cells recover
slowly. This hypothesis supports intermittent dosing of HSP90
inhibitors. When BT-474 tumor-bearing animals were adminis-
tered NVP-AUY922 weekly at doses that cause tumor con-
centrations to reach 1,000 times the GI50  value for
approximately 2 days, significant tumor growth was not
observed for about 1 week. In addition, the weekly schedule
was well tolerated. Therefore, an NVP-AUY922 intermittent
dosing regimen gives optimal tolerability without significantly
affecting efficacy. This has also been found to be the case for
other HSP90 inhibitors such as 17-AAG, which is being
administered in an intermittent dose regimen [35]. Overall, our
data offer further support for NVP-AUY922 to enter clinical
trials.
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Figure 3
Analysis of the kinetics of HSP70 induction and ERBB2 degradation following a singe dose of NVP-AUY922 Analysis of the kinetics of HSP70 induction and ERBB2 degradation following a singe dose of NVP-AUY922. BT-474 tumor-bearing animals were 
administered 50 mg/kg NVP-AUY922 at 0 hours. (a) The protein levels of HSP70 were determined by immunohistochemistry during the following 
week. (b) The quantification of the protein levels of HSP70. (c) ERBB2 protein levels were determined by immunohistochemistry and Western blot 
analysis. (d) The lowest single dose of NVP-AUY922 which mediates HSP90-p23 dissociation and reduced AKT phosphorylation was determined 
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Figure 4
Antitumor effect and tolerability of NVP-AUY922 in a BT-474 human breast cancer xenograft model Antitumor effect and tolerability of NVP-AUY922 in a BT-474 human breast cancer xenograft model. BT-474 cells were inoculated subcutaneously 
in female nude mice carrying an estrogen-release pellet. When the tumors reached 100 to 200 mm3, drug treatment was initiated. Each group con-
sisted of eight animals. NVP-AUY922 was administered (a) as a single injection, (b) three times per week (3qw), or (c) once per week (qw) at the 
indicated dose levels. Tumor volumes and body weights were measured three times per week. Each point represents the mean ± standard error of 
the mean (SEM). Arrows in right panels indicate NVP-AUY922 treatment days. Asterisks indicate statistical significance compared with vehicle-
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